Article

A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination.

Center for Cancer Immune Therapy (CCIT), Department of Hematology, 54P4, Copenhagen University Hospital, Herlev, Denmark.
The Journal of Infectious Diseases (Impact Factor: 5.85). 08/2011; 204(3):488-9. DOI: 10.1093/infdis/jir274
Source: PubMed
0 Bookmarks
 · 
124 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathogen persistence in immune-competent hosts represents an immunological paradox. Increasing evidence suggests that some pathogens, such as, Leishmania major (L. major) have evolved strategies and mechanisms that actively suppress host adaptive immunity. If this notion is correct conventional vaccination therapies may be ineffective in enhancing host immunity, unless natural processes that suppress host immunity are also targeted therapeutically. The key problem is that the basis of pathogen persistence in immune-competent individuals is unknown, despite decades of intense research. This fact, coupled with poor health care and a dearth of effective treatments means that these diseases will remain a scourge on humans unless a better understanding of why the immune system tolerates such infections emerges from research. Indoleamine 2,3-dioxygenase (IDO) has been shown to act as a molecular switch regulating host responses, and IDO inhibitor drugs shown to possess potential in enhancing host immunity to established leishmania infections. It is hoped that this review will help stimulate and help generate critical new knowledge pertaining to the IDO mechanism and how to exploit it to suppress T cell mediated immunity, thus offer an innovative approach to studying the basis of chronic leishmania infection in mice.
    Journal of Biomedical Science 01/2012; 19:5. · 2.46 Impact Factor

Full-text

View
2 Downloads
Available from